| |
|
|
|
Xtalks, online
2023 -9-18
Postpartum depression affects 14 percent of women and is unique in that it can be a devastating disease to both mother and child. It impairs maternal functioning, is associated with poor nutrition and health in the offspring and can interfere with breastfeeding, maternal-infant bonding and the care of the infant. In addition, postpartum depression is associated with abnormal development, cognitive impairment and psychopathology in children. Postpartum depression affects 14 percent of women. Among patients with postpartum depression, onset occurs before or during pregnancy in approximately 50 percent.
This webinar will provide an overview of the perinatal period and its associated psychiatric conditions, focusing on perinatal mood disorders. The featured speakers will discuss the current landscape of available therapies for perinatal mood disorders, current gaps in treatment, the regulatory landscape and considerations for clinical trials.
Attendees will learn first-hand from members of a multidisciplinary team that successfully support peripartum related clinical trials about the following:
Different conditions that are associated with perinatal period:
Perinatal insomnia
Perinatal mood disorders
Perinatal anxiety
Postpartum psychosis
Therapies available:
Psychotropics
Specialised treatments
Digital therapeutics
Register to gain insights into perinatal mood disorders, available therapies and clinical trial considerations from a multidisciplinary team in this webinar.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dr. Monica Lee, MD, Medical Director, Medical Affairs, ICON plc Dr. Louisa Steinberg, MD, PhD, Senior Director, Drug Development and Consulting Services, ICON plc
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -9-18
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|